A clinical trial to test the antibiotic dalbavancin for safety and efficacy in treating complicated Staphylococcus aureus (S. aureus) bacteremia has begun. The trial will enroll 200 adults hospitalized with complicated S. aureus infection at approximately 20 trial sites around the United States. The trial is being sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
S. aureus is a leading cause of antibiotic-resistant infection….
Science23 hours ago
Russian filmmakers head to Earth from ISS – The West Australian
Entertainment23 hours ago
Project star reveals private heartache – NEWS.com.au
Business20 hours ago
‘Unintentional gift’: US steps into China’s bitcoin breach – NEWS.com.au
Western News16 hours ago
Kids at risk as speedsters ignore school zones